X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Solifenacin Succinate is a muscarinic receptor antagonist and tamsulosin is an alpha-1A and alpha-1B adrenergic receptor antagonist used in combination to treat benign prostatic hyperplasia.
Lead Product(s): Solifenacin Succinate,Tamsulosin
Therapeutic Area: Urology Product Name: Vesomni-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Adamed Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
Solifenacin succinate is a muscarinic 3 receptor antagonist which works to decrease bladder activity by inhibiting contraction of the smooth muscle wall surrounding the bladder.
Lead Product(s): Solifenacin Succinate
Therapeutic Area: Urology Product Name: VESIcare-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2023
Details:
Solifenacin is a muscarinic receptor antagonist and tamsulosin is an alpha-1A and alpha-1B adrenergic receptor antagonist used to treat benign prostatic hyperplasia.
Lead Product(s): Tamsulosin,Solifenacin Succinate
Therapeutic Area: Urology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
Solifenacin Succinate, an oral tablet, and generic version of Vesicare, a muscarinic antagonist, is launched to treat symptoms of overactive bladder, such as frequent or urgent urination, and incontinence (urine leakage).
Lead Product(s): Solifenacin Succinate
Therapeutic Area: Urology Product Name: Vesicare-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2022
Details:
Solifenacin succinatei immediate release tablet is a muscarinic receptor antagonist and Mirabegron capsule is a potent and selective β3-adrenoceptor agonist, indicated for the treatment of overactive bladder.
Lead Product(s): Solifenacin Succinate,Mirabegron
Therapeutic Area: Urology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2022
Details:
Solifenacin Succinate Tablet is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Lead Product(s): Solifenacin Succinate
Therapeutic Area: Urology Product Name: VESIcare-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2021
Details:
Solifenacin succinate is a muscarinic 3 receptor antagonist which works to decrease bladder activity by inhibiting contraction of the smooth muscle wall surrounding the bladder.
Lead Product(s): Solifenacin Succinate
Therapeutic Area: Urology Product Name: Vesicare-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2020
Details:
VESIcare LS is an oral suspension dosage form that was specifically developed to facilitate dosing and administration in the pediatric population.
Lead Product(s): Solifenacin Succinate
Therapeutic Area: Urology Product Name: VESIcare LS
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
